Missing one dose likely wont derail your progress, but frequently interrupting your oral semaglutide dose schedule can reduce long-term effectiveness
This smart signal does three jobs at once
They will discuss your current weight, lifestyle factors, and any ongoing treatments
Are GLP-1s prohibited in sport
You shouldnt take these medications if you: Are pregnant, breastfeeding, or trying to get pregnant Have a family or personal history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) Have a known allergy to any ingredients in the medication Have a personal or family history of pancreatitis GLP-1 agonists cost and accessibility While these drugs can be highly effective, they can also be expensive
NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
